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Niemann-Pick type C (NP-C) disease is a fatal genetic lipido-
sis for which there is no Food and Drug Administration (FDA)-
approved therapy. Vorinostat, an FDA-approved inhibitor of
histone deacetylases, ameliorates lysosomal lipid accumulation
in cultured NP-C patient fibroblasts. To assess the therapeutic
potential of histone deacetylase inhibition, we pursued these in
vitro observations in two murine models of NP-C disease.
Npc1nmf164mice,which express amissensemutation in theNpc1
gene, were treated intraperitoneally, from weaning, with the
maximum tolerated dose of vorinostat (150 mg/kg, 5 days/
week). Disease progression was measured via gene expression,
liver function and pathology, serum and tissue lipid levels, body
weight, and life span. Transcriptome analyses of treated livers
indicatedmultiple changes consistent with reversal of liver dys-
function that typifies NP-C disease. Significant improvements
in liver pathology and function were achieved by this treatment
regimen; however, NPC1 proteinmaturation and levels, disease
progression, weight loss, and animalmorbidity were not detect-
ably altered. Vorinostat concentrations were >200 M in the
plasma compartment of treated animals but were almost 100-
fold lower in brain tissue. Apolipoprotein Bmetabolism and the
expression of key components of lipid homeostasis in primary
hepatocytes from null (Npc1/) and missense (Npc1nmf164)
mutant mice were altered by vorinostat treatment, consistent
with a response by these cells independent of the status of the
Npc1 locus. These results suggest that HDAC inhibitors have
utility to treat visceral NP-C disease. However, it is clear that
improved blood-brain barrier penetration will be required to
alleviate the neurological symptoms of human NP-C disease.
Histone deacetylase (HDAC)5 inhibitors were initially iden-
tified as treatments for a variety of proliferative diseases,
including T-cell lymphoma and other cancers (1). The mecha-
nismof efficacy primarily reflects changes in the transcriptional
program of rapidly growing cells and, in some cases, results in
altered expression of 2–10% of the genome (2, 3). Subsequently,
intervention at the histone acetylation/deacetylation axis of
gene expression has been successfully applied to many unre-
lated diseases (4). Neurological disorders such as Alzheimer’s
disease, Huntington’s disease, Parkinson’s disease, amyo-
trophic lateral sclerosis, and Friedrich’s ataxia have all been
found to respond to HDAC inhibitors (4–6). The primary
mechanism bywhichHDAC inhibitors influence these diseases
remains undetermined and may well be multivariate. In some
disorders (e.g. cystic fibrosis), the treatment is associated with
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alterations at the proteostatic level due in part to activation of
chaperone-mediated refolding pathways (7).
Niemann-Pick typeC (NP-C) disease is a rare lysosomal stor-
age disorder typified by defective subcellular transport of cho-
lesterol and sphingolipids as well as premature demise due to
central nervous system (largely cerebellar) impairment (8).
Autosomal recessive mutations in the NPC1 and NPC2 genes
confer 95 and 5% of NP-C disease cases, respectively. Both
genes are strikingly conserved throughout evolution (from
yeast to humans), although their precise functions remain elu-
sive (9, 10). We have proposed that variation in the activity of
additional genes influences NP-C disease severity, and these
loci represent novel therapeutic interventions (11). To identify
such NP-C disease modification pathways, we have used a
model system-based approach in the yeast Saccharomyces
cerevisiae. Our “exacerbate-reverse” strategy successfully iden-
tified 13 genetic loci whose individual absence conferred com-
plete inviability to the yeast deletion of theNPC1 ortholog con-
ditional upon sterol loading. This approach identified the status
of histone acetylation as a key component of lipid accumulation
in yeast and in cultured human fibroblasts that are deficient in
the NP-C pathways (11). We and others have demonstrated
that histone deacetylase inhibition by a variety of pharmacolog-
ical agents normalizes lipid homeostasis in rapidly growing
immortalized cell lines derived from patients with NP-C dis-
ease (11–13). These studies have progressed to the extent that
the FDA-approvedHDAC inhibitor vorinostat (suberoylanilide
hydroxamic acid, Zolinza) is the focus of a clinical trial for
safety and tolerability in adult NP-C patients (ClinicalTrials.gov
number NCT02124083).
Multitissue lipid accumulation and neurodegeneration
define NP-C disease. The aberrant subcellular lipid storage is
clearly associated with transcriptional dysregulation of numer-
ous genes, including sterol regulatory element-binding protein
targets, such as HMG-CoA reductase (HMGCR) and the low
density lipoprotein receptor (LDLR) (14, 15). Any candidate
intervention that can restore lipid homeostasis in cultured cells,
however, must also be tested for an impact on NP-C disease
pathology in an in vivomodel. This is particularly critical given
the challenge of predictingwhether results in cell culturewill be
conserved in human trials (16). Here we describe the impact of
vorinostat in a murine model of NP-C disease caused by a mis-
sense mutation in the Npc1 gene. We show that this FDA-ap-
proved HDAC inhibitor normalizes hepatic transcriptional
regulation of cholesterol, corrects apolipoprotein B homeosta-
sis, and improves liver function and pathology, thus raising the
possibility that this intervention may treat visceral NP-C dis-
ease. With the regimens used here, however, there was no
accompanying improvement in mortality or morbidity, proba-
bly due to the poor bioavailability of this drug to brain tissues.
Overall, these studies establish HDAC inhibition as an attrac-
tive approach for treatment of NP-C disease while emphasizing




mouse, NP-C disease arises from amissensemutation at codon
1005 inNpc1 that resembles several NPC1missense mutations
that cause NP-C disease in humans (17). Specifically, the
murine aspartic acid-to-glycine NPC1D1005G variant is contex-
tually similar to the NPC1S1004L, NPC1P1007A, and NPC1P1007L
variants associated with the juvenile form of human NP-C dis-
ease. The Npc1nmf164 mouse model presents with a less severe
form of the disease than theNpc1/murine model but never-
theless exhibits an abbreviated life span, progressive weight
loss, neurological impairment, and cellular lipid accumulation
compared with control littermates (17).
In contrast to theNpc1/mutantmousemodel,Npc1nmf164
mice exhibit low but detectable levels of presumably function-
ally impaired NPC1 protein (17). To specifically determine
whether this phenotype is due to misfolding and premature
degradation of the NPC1D1005G variant, fibroblasts derived
from theNpc1nmf164mouse were treated with glycerol, a chem-
ical chaperone known to stabilize misfolded proteins (18).
Glycerol increased expression levels of theNPC1D1005G protein
compared with untreated cells (Fig. 1) and in addition pro-
moted its maturation to a higher molecular weight form. The
properties of the NPC1D1005G protein were then compared
with those of NPC1I1061T, a previously described misfolded
NPC1 variant associated with the most common form of
humanNP-Cdisease (18, 19). NPC1-deficient human osteosar-
coma U2OS cells expressing the NPC1I1061T protein were also
treated with glycerol. Expression levels of the NPC1I1061T pro-
tein were also increased with glycerol treatment (Fig. 1), con-
sistent with previous studies (18). To elucidate the possible
contributions of lysosomal and proteasomal degradation to lev-
els of the NPC1D1005G protein, the Npc1nmf164 fibroblasts were
treatedwith 3-methyladenine (an autophagy inhibitor) and two
inhibitors of the proteasome, MG132 and lactacystin. Each of
these treatments increased expression and maturation of the
NPC1D1005G protein (Fig. 1), implicating lysosomal and protea-
somal pathways in the degradation of misfolded forms of the
NPC1D1005G protein.
Vorinostat Administration in a Misfolded Protein Mouse
Model of NP-CDisease—To investigate the role of vorinostat as
an NP-C therapeutic in vivo, we first assessed toxicity of this
FIGURE 1. Refolding of NPC1D1005G mutant protein. Representative image
of 30gof total cell lysates extracted fromNpc1nmf164 fibroblasts treatedwith
5% glycerol (Gly), 10 M 3-methyladenine (3MA), 10 M MG132 (MG), and 10
M lactacystin (L) comparedwith U2OS cells expressing the NPC1I1061Tmuta-
tion in the presence and absence of 5% glycerol. Lysates were denatured at
70 °C for 10min, electrophoresed through a 3–8% Tris acetate gel, and trans-
ferred onto a Protran membrane that was incubated with NPC1 or HSP70
antibody and envisaged with chemiluminescence.
HDAC Inhibition and Niemann-Pick Disease
4396 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 292•NUMBER 11•MARCH 17, 2017
 at W
ashington U









HDAC inhibitor in theNpc1nmf164NP-Cmurinemodel follow-
ing i.p. administration in a vehicle of 45% PEG 400  10%
DMSO (hereafter called PEG/DMSO). This protocol was used
previously to deliver vorinostat across the blood-brain barrier
and inhibit themetastasis of triple-negative breast cancer to the
brain (20). 21-day-old, asymptomatic Npc1nmf164 homozygous
mutant and WT mice were injected daily with 50, 100, 150, or
200 mg/kg vorinostat for 7 days. All mice were viable after 7
days; however, we observed significant weight loss in mice
treated with 200 mg/kg vorinostat. This is in agreement with
200 mg/kg being toxic in control mice as well as in a mouse
model of Huntington’s disease (5). Using the maximum toler-
ated dose and treatment regimen, we determined whether
HDAC inhibitionwith vorinostat can impactNP-Cdisease pro-
gression. Control (WT) andNpc1nmf164mice were treated with
150 mg/kg/day vorinostat or the PEG/DMSO vehicle, 5 times/
week from P21, an age where lipid accumulation already exists
in the liver and brain (17). Treatment continued until P60, at
which point disease symptoms (i.e.weight loss, motor function
deficits) are detectable in untreated Npc1nmf164 animals (17).
Transcriptional Modulation in Response to Vorinostat—The
lysosomal sequestration of free cholesterol and other bioactive
lipids in NPC1-deficient animals has striking and chronologi-
cally early consequences in terms of gene regulation. Multiple
components of lipid homeostasis and inflammation are tran-
scriptionally up-regulated, and this dysregulation is rapidly
normalized by treatmentwith the lipid chelator, 2-hydroxypro-
pyl--cyclodextrin (14, 15). To test whether these pathways
respond to vorinostat in the liver of Npc1nmf164 mice as well as
to comprehensively explore the impact of vorinostat on hepatic
gene expression in these animals, we performedRNA-Seq anal-
ysis on RNA isolated from the livers of vorinostat and vehicle-
treated Npc1nmf164 mice. The transcripts were mapped to the
mouse mm10 genome assembly, normalized, and quantified.
Approximately 16–18 million reads/sample were obtained.
Expression levels of 14,516 genes were measured, a number
comparable with the 14,326 genes measured previously in the
murine liver transcriptome (21). Expression of 844 genes (5.9%
of the transcriptome) was significantly regulated (0.6 log-fold
change, p  0.05) by vorinostat treatment, and of these 844
genes, 603 (71.4%) were up-regulated and 241 (28.6%) were
down-regulated (Fig. 2, a and b, supplemental Table S1). These
genes were classified within an extensive array of Gene Ontol-
ogy processes (Fig. 2a). Notable cellular aspects and processes
relevant to NP-C disease and HDAC inhibition include lipid
metabolism, inflammation, and histone-mediated gene expres-
sion (Fig. 2c).
Critically, the vorinostat-responsive genes include those
known to be modulated by HDAC inhibitors in previous stud-
ies. For example, the GATA-binding transcription factor
Gata1, a hallmark vorinostat-responsive gene (2, 3, 22),
was up-regulated 3.6 log2-fold (p  0.0001) in vorinostat-
treatedNpc1nmf164mice compared with PEG/DMSO-treated
Npc1nmf164mice (Fig. 2c). As observed previously (23, 24), early
growth response-1 (Egr1) and amyloid  precursor-like protein
1 (Aplp1) were elevated 1.2 log2-fold (p 5.67 104) and 2.56
log2-fold (p  1.95  1019), respectively, after vorinostat
treatment (Fig. 2c). Transcription of the aryl hydrocarbon
receptor nuclear translocator-like protein 1 (ARNTL, also
referred to as BMAL1) is repressed by HDAC3 (25) and was
elevated 2.59 log2-fold (p  1.18  107) after treatment with
vorinostat (Fig. 2c). Likewise, we determined that vorinostat
reduced transcription of the minichromosome maintenance
protein-2 (MCM2) by 0.67 log2-fold (p  0.0015) and the
TATA-box-binding protein TAF6L by 0.56 log2-fold (p 
0.004) compared with PEG/DMSO-treated mice (Fig. 2c), con-
sistent with the previously observed down-regulation of these
genes by HDAC inhibitors (26, 27). Additionally, the cyclin D1
(Ccnd1) gene has been shown to decrease in expression by
HDAC inhibition (28); here vorinostat reduced Ccnd1 expres-
sion 1.34 log2-fold (p  1.8  106) (Fig. 2c). It is clear from
these responses that a variety ofHDAC isoforms, and thus their
transcriptional targets, were affected by the treatment protocol
in place, as would be anticipated for the impact of a global
HDAC inhibitor like vorinostat.
To determine the therapeutic potential of vorinostat, we
investigated the overlap of vorinostat-mediated gene expres-
sion and candidate biomarkers previously shown to be tran-
scriptionally dysregulated in NP-C disease. Lyz1 (lysozyme 1)
transcript levels are up-regulated in the liver and brain of the
Npc1/mouse (29), and plasma lysozyme activity is increased
in the Npc1/ mouse (30). Vorinostat treatment reduced
hepatic expression of Lyz1 by 1.1 log2-fold (p 4.37 104) in
Npc1nmf164mice compared with vehicle control (Fig. 2c). Like-
wise, the sterol regulatory element-binding factor (SREBF1) is a
transcription factor that regulates cholesterol synthesis and is
up-regulated in NPC1-deficient hepatocytes (31), and Srebf1
expression was reduced with the vorinostat treatment 0.64
log2-fold (p 0.02) compared with vehicle-treated Npc1nmf164
mice (Fig. 2c). In addition, the genes encoding oxysterol-bind-
ing proteinOSBPL3 and the perilipin PLIN4were up-regulated
in independent studies of the liver of the Npc1/ mouse (29,
32), and we show here that the vorinostat treatment reduced
expression of Osbpl3 and Plin4 by 1.4 log2-fold (p  2.86 
107) and 1.3 log2-fold (p  1.44  105), respectively, in
Npc1nmf164 mice (Fig. 2c).
Similarly, several transcriptional pathways associated with
inflammation (a characteristic of chronic NP-C disease) were
normalized by treatment of the Npc1nmf164 mouse with vori-
nostat. For example, expression levels of four genes (metallo-
proteinase matrix-15 (Mmp15), CD276 antigen (Cd276), and
histocompatibility antigens H2-Ab1 and H2-Eb1) that were
consistently shown to be up-regulated in Npc1/ mice (29, 32)
were down-regulated in vorinostat-treated Npc1nmf164 mice
compared with vehicle-treated Npc1nmf164 mice (Fig. 2c).
Expression levels of three additional pro-inflammatory CD
antigen genes (Cd8a,Cd79b, andCd74) were similarly reduced
by vorinostat (Fig. 2c). Two S100a genes (S100a8 and S100a9)
that are targets ofNFk and critical components of the immune
response to liver damage (33) were up-regulated with vorinos-
tat treatment (Fig. 2c). The cathelicidin antimicrobial peptide
gene (Camp) is required for inflammatory response regulation;
expression of CAMP was up-regulated in two studies of the
Npc1/mouse (29, 32) and down-regulated in theNpc1nmf164
mice treated with vorinostat. These results suggest that vori-
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nostat activates an anti-inflammatory response as a conse-
quence of NP-C disease in the Npc1nmf164 mouse.
TranscriptionalModulation of Cholesterol Metabolism—We
used the Web Gene Ontology Enrichment Analysis Tool Kit
(34) to identify pathways statistically overrepresented within
the 844 vorinostat-regulated genes in the liver transcriptome of
Npc1nmf164 mice. In addition to amino acid metabolism (p 
0.0323), four pathways associated with an anti-inflammatory
response were enriched: GPCRs class A rhodopsin-like (p 
0.0008), GPCRs non-odorant (p 0.0026), GPCRs peptide (p
0.0323), and chemokine signaling pathway (p  0.0082). Of
particular relevance to NP-C disease, the enrichment analysis
revealed that genes critical to the biosynthesis of cholesterol
were down-regulated (p 0.0014) (Fig. 2c). qRT-PCR analysis
for seven key genes (Hmgcs1, Hmgcr, Mvk, Mvd, Idi1, Lss, and
Cyp51) was conducted on sets of three randomly selected mice
from the RNA-Seq analysis (Fig. 3, a–g). Vehicle- and vorinos-
tat-treatedWTmice were included to determine whether vori-
FIGURE 2. Vorinostat administration from P21 to P60 alters the liver transcriptome of Npc1nmf164 mice. a, quantification of the diversity of biological
processes regulated by vorinostat as assigned using PANTHER (19). b, heat map depicting the relative repression or induction of 844 transcripts that were
differentially expressed in the liver by0.6 log2 ratio -fold change (p 0.05) between the vehicle- and vorinostat-treatedNpc1
nmf164mice (n 7, bothgroups).
c, functional gene annotation clustering performed on 10 genes identified in cellular functions associated with inhibition of histone deacetylation, 19 genes
with cellular functions associated with lipid metabolism, and 16 genes with cellular functions associated with inflammation. The scale bar indicates propor-
tional read counts, with red andwhite tones representing down-regulated and up-regulated genes, respectively; this scale bar applies to b and c.
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nostat regulates these cholesterol biosynthesis genes indepen-
dent of the status of the NPC1 pathway.
Our analyses suggest that the cholesterol biosynthetic path-
way is significantly up-regulated in the Npc1nmf164model, pre-
sumably in response to the lysosomal accumulation of choles-
terol in association with reduced free cholesterol in regulatory
pools such as the ER. Indeed, expression levels of Hmgcs1,
Hmgcr, Mvk, Mvd, Idi1, Lss, and Cyp51 were significantly
up-regulated in the mutant mice relative to WT (Fig. 3, a–g),
ranging from an increase of 2-fold to an increase of 5.1-fold.
Impressively, vorinostat treatment significantly decreased the
expression of all seven genes toward WT levels, with -fold
change ranging from 1.6- to 2.8-fold. Moreover, these changes
were only identified in Npc1nmf164 mice; expression levels of
these seven genes in WT mice were not affected by vorinostat
treatment. In addition, we measured expression of Ldlr, a gene
that is strongly up-regulated in NP-C disease (14, 15); LDLR
was up-regulated 1.9-fold in vehicle-treated Npc1nmf164 com-
pared with vehicle-treated WT mice (p  0.014), and down-
regulated 1.7-fold in vorinostat-treated Npc1nmf164 compared
with vehicle-treatedNpc1nmf164mice (p 0.044) (Fig. 3h). Col-
lectively, these results have threemajor implications. First, cho-
lesterol homeostatic genes are elevated in Npc1nmf164 mice at
P60. Second, vorinostat does not regulate expression of choles-
terol metabolism genes in WT mice. Third, and most impor-
tantly, upon treatment with vorinostat, eight genes critical to
cholesterol homeostasis and NP-C disease were down-regu-
lated to WT levels.
Lipid Metabolism Is Fundamental to the Vorinostat In-
teractome—To identify the core genes in the vorinostat inter-
actome, we used Phenolyzer (35) to visualize gene-gene inter-
actions, protein-protein interactions, and transcriptional regu-
lation among the 844 genes in the vorinostat interactome (Fig.
2a). This analysis distinguished Cyp27b1, Hmgcr, Pnpla3, and
Chka as the core hubs in the vorinostat interactome, each with
20 interactions within the interactome (Fig. 4). Cyp27b1
FIGURE3.Vorinostat normalizesgeneexpressionof key components of cholesterol homeostasis. 80ngof RNA from the indicated animalswere assessed
for gene expression at P60 using qRT-PCR relative to GAPDH (PCR primers are described under “Experimental Procedures”). Vehicle-treated WT mice were
assigned abaseline expressionof 1.a–g, cholesterol biosynthesis genes thatwere significantly enriched in RNA-Seq analysis (Hmgcs,Hmgcr,Mvk,Mvd, Idi1, Lss,
and Cyp51). h, Ldlr. All groups are n 3 with data shown as mean S.D. (error bars) *, p 0.05, Student’s t test.
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encodes a member of the cytochrome P450 superfamily of
enzymes that hydroxylates 25-hydroxyvitamin D3 and regu-
lates the level of biologically active vitaminD derived from cho-
lesterol. Interestingly, vitamin D deficiency is associated with
toxic lipid accumulation in chronic liver disease (36). Hmgcr
encodes the rate-limiting enzyme in cholesterol biosynthesis
that is consistently up-regulated in NP-C disease (14, 15), and
we show here that vorinostat treatment restores this dysregu-
lation to normal levels (Fig. 3b). Pnpla3 encodes a patatin-like
phospholipase that is a genetic risk factor for lipid-mediated
liver disease wherein overexpression confers hepatic steatosis
(37). Chka encodes choline kinase , one of two mammalian
enzymes that catalyze the phosphorylation of choline to phos-
phocholine in the biosynthesis of the major membrane phos-
pholipid, phosphatidylcholine (38). The hubs of the vorinostat
interactome are all associated with lipid metabolism; specifi-
cally, our identification of Hmgcr as a mediator of vorinostat-
mediated down-regulation of cholesterol biosynthesis aswell as
a key hub in the vorinostat interactome indicates that regula-
tion of cholesterol biosynthesis is fundamental to the impact of
vorinostat on NP-C disease.
Vorinostat Improves Liver Health—To determine whether
the transcriptional regulation of cholesterol metabolism by
vorinostat has functional consequences, we measured serum
levels of alanine aminotransferase (ALT), an enzyme that is
elevated in NP-C disease as a consequence of liver damage (39).
SerumALT levels were significantly higher (73.9%) in the PEG/
DMSO-treated Npc1nmf164 mice compared with PEG/DMSO-
treated control mice. Vorinostat treatment significantly
reduced serum ALT levels in Npc1nmf164 mice by 25.7% (Fig.
5a). Furthermore, vorinostat treatment significantly reduced
serum total cholesterol in Npc1nmf164 mice by 22%, indepen-
dent of HDL cholesterol or triglyceride concentrations (Fig. 5,
b–d).
Thin section H&E staining of fixed liver tissue revealed
the marked accumulation of lipid-laden cells in untreated
Npc1nmf164mice at P60 (Fig. 5e), characteristic of lipid accumu-
lation at this stage of the disease in this mouse model (17).
Treatment of Npc1nmf164 mice with vorinostat convincingly
and significantly reduced the prevalence of lipid-laden cells by
48.9% (p 0.001) and elevated the presence of healthy hepato-
cytes, relative to vehicle controls (Fig. 5e). Taken together, the
transcriptional normalization of hepatic cholesterol homeo-
static genes and the reductions in serum cholesterol and ALT
levels (liver function) in conjunction with improved liver histo-
pathology indicate a marked recovery from visceral NP-C dis-
ease due to vorinostat treatment.
To determine whether the vorinostat-mediated changes in
liver heath correlate with changes in total lipid accumulation in
vivo, we quantified levels of free cholesterol, sphingomyelin,
sphingosine, glucosylceramide, and lactosylceramide using
GC/MS and LC/MS. These lipids are biochemical hallmarks of
late stage NP-C disease in the liver (8). Because the status of
these lipids has not been reported for the Npc1nmf164 mouse at
P60, we first determined that these lipids were significantly
increased in vehicle-treated Npc1nmf164 mice compared with
vehicle-treated WT mice (Fig. 6, a–e). In accordance with the
Npc1/ and Npc1I1061T mouse models of NP-C disease (14,
19, 40), the Npc1nmf164 mice exhibit increased levels of these
lipids relative to WT mice (Fig. 6, a–e). Vorinostat did not
detectably alter lipid levels in WT or Npc1nmf164 mice (Fig. 6,
a–e). To further investigate a hallmark lipid using an indepen-
dent method, we assessed free cholesterol levels using fluores-
cent microscopy. Filipin, a fluorescent stain for unesterified
cholesterol, is a key tool used in the diagnosis of NP-C patients
(8). As expected, we observed increased filipin fluorescence in
vehicle-treated Npc1nmf164 mice compared with vehicle-
treatedWTmice (Fig. 6, f and g). However, filipin fluorescence
FIGURE 4. Lipid metabolism is fundamental to the vorinostat interactome. The 844 genes in the vorinostat interactome were processed through Pheno-
lyzer (35) to visualize the 50 most interactive genes based on gene-gene interactions, protein-protein interactions, and transcriptional regulation within the
interactome. This analysis distinguished four lipidmetabolism genes (Cyp27b1, Hmgcr, Pnpla3, and Chka) as the core hubs (indicated in blue) in the vorinostat
interactome, each with more than 20 interactions within the interactome. The size of the nodes represents the number of interactions.
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did not indicate any change in free cholesterol levels after vori-
nostat treatment. These results indicate that vorinostat did not
detectably reduce lipid accumulation in the liver using this
treatment regime from P21 to P60. Together, these results of
reduced ALT levels, reduced number of lipid-laden cells, and
increased number of healthy hepatocytes coincident with no
apparent reduction in total mass of unesterified cholesterol
suggest that vorinostat reproportions lipids, a phenomenon
that would be consistent with partitioning of unesterified cho-
lesterol in Kupffer cells by cyclodextrin (41).
Vorinostat Treatment Does Not Delay Weight Loss or Extend
Life Span—To determine the effect of vorinostat on the life
span of the Npc1nmf164 mice, we monitored the weight of vori-
nostat- and PEG/DMSO-treated mice during an extended
treatment period from P21 to P90 using the regimen described
above (150 mg/kg/day vorinostat in PEG/DMSO vehicle, 5
times/week). In agreement with our prior toxicity study, vori-
nostat-treated WT mice continued to gain weight beyond 10
weeks (Fig. 7a) andwere not neurologically impaired compared
with vehicle-treatedmice. Relative to vehicle-treatedWTmice,
vehicle-treated Npc1nmf164 mice significantly lost weight
between 10 and 13 weeks (p 0.0002), a result consistent with
prior characterization of the Npc1nmf164 mice (17). There was
no delay in the weight loss of vorinostat-treated Npc1nmf164
mice at any point during the treatment (Fig. 7a); treated and
untreated animals lost weight and exhibited ataxia to similar
levels from 9 to 10 weeks until death. Therapies that have
delayed weight loss have also extended life span (14, 42); thus,
the absence of change with vorinostat treatment would predict
that this intervention protocol does not extend life span.
Indeed, vorinostat-treated Npc1nmf164 mice survived 94  7
days (n  8), a time range that is not different than the 94 
4-day (n 5) life span of untreated Npc1nmf164 mice.
Penetration of the Blood-Brain Barrier by Vorinostat—
Despite its beneficial effect on the liver, the lack of effect of
vorinostat treatment on weight and life span of the Npc1nmf164
mouse suggests that the drug fails to reach a concentration in
the brain required to reverse the overall impact of the disease.
Previously, a concentration of 5–10 M vorinostat was
described as sufficient to limit lipid accumulation in cultured
NP-C patient fibroblasts (11–13). To determine the drug con-
centration achieved in the brain, we quantified vorinostat in
plasma and brain of treated Npc1nmf164 mice at P21 (Fig. 7b).
The levels of vorinostat in the plasma at 0.5, 1, 2, and 4 h after
injection were 222.29, 17.39, 3.01, and 0.97M. In marked con-
trast, the levels of vorinostat in the brain in the same animals
were 3.16, 0.23, and 0.12 M, at 0.5, 1, and 2 h after injection,
respectively, and were below the minimum detection level of
the assay at 4 h (Fig. 7c). These results indicate a half-life of
vorinostat that is60 min. Our findings of rapid clearance and
5% brain penetration, compared with plasma, in Npc1nmf164
mice are in accordancewith observations in normalmice and in
a murine model of Huntington’s disease (43, 44).
Improved Liver Function Is Independent ofNpc1 Expression—
To investigate the mechanism by which vorinostat reduced
ALT levels, we measured Npc1 mRNA and protein levels to
test the hypothesis that vorinostat elevated expression of the
NPC1D1005G variant in the Npc1nmf164 mouse. To determine
FIGURE 5. Vorinostat treatment improves liver function in Npc1nmf164
mice. Animals were treated with either vehicle (PEG/DMSO) or 150 mg/kg
vorinostat from P21 to P60, at which point serum was harvested from sacri-
ficed animals. Liver function was evaluated via levels of ALT expressed as
international units/liter (IU/L; a). Total cholesterol, HDL cholesterol, and trig-
lycerides (b–d) were measured and are expressed as mmol/liter. All data are
shown asmean S.E. (error bars) forWT PEG/DMSO (n 5), WT vorinos-
tat (n 5),Npc1nmf164 PEG/DMSO (n 4), andNpc1nmf164 vorinostat (n
5). *,p0.05, Student’s t test. e, fixed liver tissuewasparaffin-embedded, and
5-msectionswere stainedwith H&E. Representative images are shown. The
prevalence of lipid-laden cells was expressed as a fraction of total cells per
field (	3000) and quantified using SlidePath tissue image analysis (Leica Bio-
systems, version 2.0) software at 20 magnification. Data are shown in f as
mean  S.D. (error bars) from 10–15 random fields/animal with 3 animals/
treatment group. *, p  0.001, Student’s t test. The inset panels represent a
80 magnification of the field of view, focusing on the lipid laden cells.
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whether vorinostat up-regulated Npc1 mRNA expression, we
measuredmRNA levels of NPC1 by quantitative real-time PCR
(Fig. 8a). Expression ofNpc1wasnot affected in either genotype
with vorinostat treatment, although Npc1 mRNA expression
was modestly elevated in vehicle-treatedNpc1nmf164 compared
with vehicle-treated WT mice (p  0.066). Quantification
of Western blotting analysis of liver protein extracts from
treated and untreated animals (n 7/group) indicated that the
vehicle-treated Npc1nmf164 mouse expressed 19% of the
amount of Npc1 expressed by vehicle-treated WT mice (p 
5.76  107; Fig. 8, b and c), consistent with previous reports
that the Npc1nmf164 mouse expressed 10–15% of WT levels of
NPC1 (17). However, our analysis indicated equivalent steady
state levels of NPC1 protein in vorinostat-treated liver and
vehicle control-treated livers. The mRNA levels of Npc2 were
4.7-fold higher (p 0.016) in vehicle-treated Npc1nmf164 com-
pared with vehicle-treated WT mice, a result that has been
reported previously for theNpc1/ null and theNpc1pf/pfmis-
sensemutantmousemodels ofNP-C disease (45, 46). However,
there was no significant change in expression of Npc2 in vori-
nostat-treated Npc1nmf164 compared with vehicle-treated
Npc1nmf164 mice (Fig. 8d). These results suggest that the
improvementsinlipidmetabolismandliverfunctionoccurinde-
pendently of the concentration of the NPC1D1005G protein and
are not a consequence of vorinostat regulating theNPC1/NPC2
pathways at protein or mRNA levels.
Vorinostat Does Not Increase Maturation of the NPC1D1005G
Protein—To further understand the lack of impact of vori-
nostat on expression of the NPC1D1005G protein in the liver
of Npc1nmf164 mice, we investigated maturation of the
NPC1D1005G protein in the secretory pathway via two glycosi-
dase digestion assays that have been used previously to charac-
terize the NPC1I1061T protein (18, 19). First, we used endogly-
cosidase H (Endo H), an enzyme that removes immature high
mannoseN-linked glycans fromproteins. Second, we used pep-
tide:N-glycosidase F (PNGase F), an enzyme that removes all
N-linked glycan residues regardless of the glycan modification.
In livers of vehicle-treated WT mice, the NPC1 protein is gly-
cosidase-sensitive represented by amature species at	225 kDa
that is reduced to two deglycosylated species at	200 and	150
kDa in response to the Endo H and PNGase F treatments,
respectively (Fig. 8e). These results indicate that the wild-type
NPC1 protein is glycosylated in the ER and further matured in
the Golgi. Conversely, the NPC1D1005G protein in both vehicle-
FIGURE 6. Cholesterol and sphingolipid accumulation in the liver of vorinostat-treated mice.WT and Npc1nmf164 mice were treated with either vehicle
(PEG/DMSO)or 150mg/kgvorinostat fromP21 toP60, atwhich time liverswereharvested fromsacrificed animals.a–e, free cholesterol and sphingolipidswere
measuredusing LC/MS. All groups aren 5with data shownasmean S.D. (error bars). *,p 0.05, Student’s t test. f–g, unesterified cholesterolwas visualized
using filipin and quantified using densitometry software (ImageJ). All groups are n 3 with data shown as mean S.D. *, p 0.05, Student’s t test.
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and vorinostat-treatedNpc1nmf164mice is predominantly a sin-
gle species at 	150 kDa in undigested, Endo H-treated, and
PNGase F-treated samples, with electrophoretic mobility sim-
ilar to that of PNGase F-treated WT protein (Fig. 8e). These
results indicate that the majority of NPC1D1005G protein in liv-
ers ofNpc1nmf164mice lacks glycosylation and does not exit the
ER as a result of misfolding. This defect was not corrected by
vorinostat treatment.
Vorinostat Normalizes Apolipoprotein BMetabolism inNpc1
Null and Missense Mutant Hepatocytes—Inhibition of histone
deacetylation results in differential expression of 2–10% of the
genome (2, 3). In disorders such as cystic fibrosis, the success of
vorinostat treatment was, at least in part, due to activation of
chaperone-mediated refolding pathways (7). Thus far, our data
suggest that vorinostat is therapeutic via amechanism that does
not require functional NPC1 (Figs. 3 and 8). To directly test
whether residual levels of NPC1 protein impact the response to
vorinostat treatment, we compared primary hepatocytes pre-
pared from Npc1nmf164 and Npc1/ mice. In contrast to the
Npc1nmf164 mice that produce low levels of NPC1 protein, the
Npc1/model expresses a null variant of the Npc1 gene aris-
ing from a transposon insertion at the 5
 end of the gene (47).
Metabolic labeling of primary hepatocytes with [35S]methio-
nine followed by immunoprecipitation was used to quantify
newly synthesized and secreted isoforms of apolipoprotein B
(apoB100 and apoB48). These proteins are major exporters of
lipid from the liver (48). As described previously (31), the syn-
thesis of apoB100 by hepatocytes derived from Npc1/ mice
was elevated in response to the lipid accumulation underlying
NP-C disease. Similarly, secretion of newly synthesized
apoB100 was dramatically increased (507.3%, p  0.006), and
apoB48 was marginally increased (18.8%, p  0.0007) in
Npc1/ hepatocytes compared with control hepatocytes from
WT littermates (Fig. 9, a–c). Despite the absence of the NPC1
protein in these cell lines, the ex vivo treatment of 10 M vori-
nostat strikingly reduced secretion of apoB100 by 76% (p 
0.01) to control levels (Fig. 9, a–c). Interestingly, secretion of
apoB48 was slightly elevated in vorinostat-treated Npc1/
hepatocytes compared with vehicle-treated Npc1/ hepato-
cytes (23.5%, p 0.046). ApoBmetabolismwas also aberrant in
primary hepatocytes from Npc1nmf164 mice expressing the
NPC1D1005G missense mutant. Unlike the null mutant hepato-
cytes, secretion levels of apoB100 and apoB48 were signifi-
cantly reduced by 57.2% (p  0.04) and 69.6% (p  0.002),
respectively, in vehicle-treated Npc1nmf164 hepatocytes com-
pared with vehicle-treated control hepatocytes (Fig. 9, d–f).
Similar to the response ofNpc1/ hepatocytes to vorinostat,
secretion of newly synthesized apoB48 levels in media was
significantly increased (413.7%, p  0.0008) in vorinostat-
treatedNpc1nmf164 hepatocytes compared with vehicle-treated
mutant cells (Fig. 9, d–f). Clearly, vorinostat modulated the
homeostasis of apoB in both null Npc1/ and missense
Npc1nmf164 hepatocytes, further demonstrating that the mech-
anism of action of this drug is independent of NPC1.
To further investigate the efficacy of vorinostat in Npc1/
and Npc1nmf164 primary hepatocytes, we measured expression
FIGURE 7.Vorinostat does not delayweight loss or penetrate the blood-brain barrier ofNpc1nmf164mice. a, animals were treatedwith PEG/DMSOor 150
mg/kg vorinostat between P21 and P90 (3–13 weeks) and weighed weekly. Data are shown as mean S.D. (error bars) for WT PEG/DMSO (n 5), WT
PEG/DMSO (n5),Npc1nmf164PEG/DMSO (n5), andNpc1nmf164 vorinostat (n6). *,p0.05, two-way analysis of variancewith Bonferroni post hoc test.
b and c, vorinostat levels in the brain are5% of plasma levels. 150mg/kg vorinostat was administered in Npc1nmf164 mice at P21, andmean vorinostat levels
were quantified in the plasma and brain at four time points after injection (0.5, 1, 2, and 4 h).
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of several genes integral to lipid metabolism (Npc1, Hmgcr,
Abcg1, and Apob) and the cellular response to misfolded pro-
teins (CHOP). The expression of Npc1 was significantly
increased by 91% (p  0.016) in vehicle-treated Npc1nmf164
cells compared with vehicle-treated control hepatocytes, and
vorinostat did not impact these expression levels (Fig. 10a),
results that are consistent with Npc1 gene expression in the
liver of Npc1nmf164 mice compared with controls (Fig. 8a). As
expected, expression ofNpc1 was significantly reduced (81.4%,
p 0.009) in vehicle-treated Npc1/ compared with vehicle-
treated WT hepatocytes, and interestingly, albeit probably not
functional, this was significantly up-regulated following treat-
ment with vorinostat (Fig. 10a). The expression of ApoB was
significantly reduced by 50.1% (p 0.0009) inNpc1nmf164hepa-
tocytes compared withWT hepatocytes and was markedly ele-
vated by vorinostat treatment beyond control levels in both
Npc1nmf164 (p  0.0007) and Npc1/ hepatocytes (p  0.04)
(Fig. 10b). The transcription factor, CCAAT/enhancer-binding
protein homologous protein (CHOP), an indicator of ER stress
that has been associated with disrupted apoB metabolism (49),
was significantly increased in Npc1nmf164 hepatocytes (111.6%,
p 0.0006) compared withWT hepatocytes (Fig. 10c). In con-
trast, the expression of Chop was significantly reduced in
Npc1/ hepatocytes by 40.4% (p 0.03) compared with con-
trol hepatocytes. This dysregulation was reduced further in
both mutant cell types by vorinostat treatment (49.9%, p 
0.0003 in Npc1/ cells; 23.7%, p  0.001 in Npc1nmf164 cells)
(Fig. 10c). These results suggest that vorinostat transcription-
FIGURE 8. Liver recovery due to vorinostat treatment is independent of changes in expression ofNpc1orNpc2.Animalswere treatedwith either vehicle
(PEG/DMSO) or 150 mg/kg vorinostat from P21 to P60. a, liver RNA from the indicated animals was assessed for Npc1 gene expression by qRT-PCR relative to
Gapdh. All groups are n  3 with data shown as mean  S.D. (error bars). b, representative image of 30 g of hepatic protein extracted from vehicle- and
vorinostat-treated animals that was denatured at 4 °C for 30 min, subjected to electrophoresis, transferred onto PVDF membrane, and incubated with NPC1
antibody or actin antibody. c, NPC1 and actin bands were quantified relative to actin using densitometry software (ImageJ). All groups are n 7 with data
shownasmean S.E. *,p0.05, Student’s t test.d, liver RNA from the indicated animalswas assessed forNPC2geneexpressionbyqRT-PCR relative toGAPDH.
All groups are n 3 with data shown asmean S.D. (error bars). *, p 0.05, Student’s t test. e, protein from the indicated animals was extracted, treated with
glycosidase enzymes, and analyzed via SDS-PAGE/immunoblotting and probed for NPC1 expression.
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ally modulates gene expression in Npc1nmf164 and Npc1/
hepatocytes independent of the status of the NPC1 locus.
In certain instances, the transcriptional response to vorinos-
tat by primary hepatocytes wasmore striking in the presence of
residual NPC1 protein (i.e. inNpc1nmf164 hepatocytes). Relative
to controls, expression of Hmgcr was significantly reduced by
47.5% (p  0.004) in Npc1nmf164 and by 53.4% (p  0.0003) in
Npc1/ hepatocytes (Fig. 10d), consistent with previously
reported levels of processed (nuclear) SREBP2 in Npc1/
hepatocytes (31). Interestingly, vorinostat significantly in-
creased Hmgcr expression to control levels only in Npc1nmf164
hepatocytes (136.5%, p  0.002). Similarly, the expression of
Abcg1 was significantly increased in Npc1nmf164 and Npc1/
hepatocytes by 769.7% (p  3.3  105) and 206.7% (p 
0.0003), respectively, compared with control hepatocytes (Fig.
10e), results that are in agreement with the previous demon-
stration of increased expression of Abcg1, a transporter that
regulates efflux to HDL, inNpc1/ hepatocytes (50). Vorinos-
tat treatment significantly increased Abcg1 expression but only
in Npc1nmf164 hepatocytes (92.7%, p  0.001), a mechanism
consistent with observations on the anti-atherogenic effects of
HDAC inhibition (51).
Discussion
The identification of FDA-approved drugs to treat NP-C dis-
ease remains elusive; in nearly 2 decades of effort since the
molecular isolation of the NPC1 gene (52), only 2-hydroxypro-
pyl--cyclodextrin, the excipient of a failed neurosteroid
treatment (53), has progressed to a Phase 3 clinical trial. As an
alternate strategy, we applied unbiased, genome-wide, genetic
screens in yeast and identified histone acetylation as a negative
modifier of the NP-C disease pathway (11). Subsequently, we
and others translated this finding by demonstrating the efficacy
of HDAC inhibitors to reduce lipid accumulation in NP-C
patient fibroblasts (11–13). We hypothesized that this thera-
peutic effectwould be conserved in vivo and that the pathway to
regulatory approval of vorinostat for this orphan disease would
be relatively rapid and unencumbered. In the present study, we
tested the impact of intraperitoneal injection of vorinostat in
the Npc1nmf164 mouse model of NP-C disease. We carefully
reviewed toxicity and administration of vorinostat and used a
concentration and dosing regimen that was the maximum tol-
erated dose in this animal. This regimen exceeded that used to
treat murine models of cancer (the equivalent of a human dose
of 400 mg/day). We were successful in that vorinostat treat-
mentwas therapeutic for visceralNP-Cdisease, as evidenced by
normalized liver lipid homeostasis at the transcriptional level
and marked improvement of liver pathology and function.
However, aspects of disease progression such as morbidity,
mortality, and neurodegeneration were not impacted, due, at
least in part, to ineffective brain penetration.
We interpret these findings as a very promising step toward
applyingHDAC inhibitors as therapeutics for this disease; how-
ever, themanner bywhichHDAC inhibitorsmay act remains to
be determined. HDAC inhibitors impact expression of the
genome in a global fashion, with immense capacity to simulta-
neously alter numerous metabolic pathways. Indeed, our
results show that vorinostat altered the expression of 	6% of
the liver transcriptome of Npc1nmf164 mice, a result consistent
with previous reports of vorinostat regulating 2–10% of the
genome (2, 3). Most notably, we detected transcriptional regu-
lation of genes involved in cholesterol homeostasis that corre-
late with reversal of NP-C disease. The Hmgcs1, Hmgcr, Mvk,
Mvd, Idi1, Lss, Cyp51, and Ldlr genes were repressed by vori-
nostat only in the Npc1nmf164 mice, reflecting the successful
treatment of hepatic NP-C disease as well as a therapeutic
mechanism that is independent of Npc1. Interestingly, HDAC
inhibitors have also been shown to repress expression of cho-
lesterol homeostatic genes in U18666A-treated SH-SY5Y
human neuroblastoma cells (54). HDAC inhibitors can further
impact expression of the genome by directing recovery of mis-
folded mutated proteins via the induction of chaperone path-
ways (7). In Npc1nmf164 mice, the NPC1D1005G variant protein
persisted as an unglycosylated species that could be chased
through the secretion pathway into a fully glycosylated mature
species either by a refolding agent, such as glycerol, or by pro-
tection from degradation. However, our studies demonstrate
that this is not the predominant mechanism by which vorinos-
tat impacts NP-C disease in these animals.
Despite the overall transcriptional responsiveness of the
Npc1nmf164 missense mutant mouse, the vorinostat treatment
protocol used here did not detectably alter hepatic expression
of Npc1 at either mRNA or protein levels or in terms of its
maturation through the secretion pathway.Moreover, whenwe
compared apoB homeostasis in primary hepatocytes from both
missense (Npc1nmf164) and null (Npc1/) mice, we concluded
that vorinostat normalized both genotypes, relative to their
own age-, gender-, and background-matched controls. Inter-
estingly, apoB levels were significantly increased in Npc1/
mice in the BALB/c background and significantly decreased in
Npc1nmf164 mice in the C57BL/6 background, differences that
may be consequences of the strain background and/or theNpc1
mutation. There is precedence for the impact of mouse back-
FIGURE 9. Vorinostat modulates apoB metabolism in Npc1nmf164 and
Npc1/ hepatocytes. Hepatocytes were isolated from livers of Npc1nmf164
and Npc1/mice, incubated for 24 h in DMEM 10% FBS with 10 M vori-
nostat or DMSO, and labeledwith [35S]methionine inmethionine-free DMEM
for 2 h. Equal radiolabeled protein was separated on a 4% SDS-polyacryl-
amide gel to distinguish apoB100 and apoB48 in mutant mice relative to
appropriateWT controls. a–c, newly synthesized and secreted apoB inmedia
of Npc1/ hepatocytes. d–f, newly synthesized and secreted apoB in media
of Npc1nmf164 hepatocytes. Data represent mean cpm S.D. (error bars) from
triplicates. *, p 0.05, Student’s t test.
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ground in the context of Npc1 missense mutations (e.g. differ-
ent lipidomic profiles in NPC1I1061T mice in the BALB/c and
C57BL/6 backgrounds) (19). Similarly, there is precedence for
varying effects of the	300 disease-causing mutations inNPC1
on the clinical progression of NP-C disease (8, 55–57). Regard-
ing the efficacy of vorinostat, the extent of misfolding and fea-
sibility of refolding will be critical to decipher for different
mutations in NPC1. Our results suggest that vorinostat would
be therapeutic in the liver of all NP-C patients regardless of
mutation because the mechanism underlying improvement
was predominantly independent of Npc1 expression.
It is clear that the bioavailability and stability of vorinostat
represent a significant but, we believe, surmountable hurdle to
further progress. We determined that i.p. administration and a
PEG/DMSO vehicle result in vorinostat levels at5 M in the
brain, 30 min after injection, a result in stark contrast to the 60
M concentration in plasma at the same juncture. Concentra-
tions of 5 M are necessary to reduce lipid accumulation with
24-h treatment in cell culture (11–13). Given the 12-min half-
life of vorinostat in rats and dogs (58) compared with the effec-
tively infinite half-life in cell culture, it is plausible that5M is
necessary to reduce lipid accumulation in the murine brain.
Interestingly, using the PEG/DMSO vehicle and the 150 mg/kg
dose in this study, i.p. administered vorinostat reduced the
tumor size in the brain of a mouse model of brain cancer (20), a
result that was attributed to a disrupted blood-brain barrier in
brain cancer models (44). It is widely accepted that the murine
and feline models of NP-C disease do not have a compromised
blood-brain barrier (59, 60). The blood-brain barrier could be
circumvented by a variety of strategies. Rescue of neurodegen-
erative symptoms in mouse models of Huntington’s disease
have been accomplished by dissolving vorinostat in 2-hydroxy-
propyl--cyclodextrin (5, 43). This is interesting, because
although 2-hydroxypropyl--cyclodextrin is a compound not
known to cross the blood-brain barrier, perhaps it improves
blood-brain barrier penetration of vorinostat in the Hunting-
ton’s disease studies. Intriguingly, 2-hydroxypropyl--cyclo-
dextrin alone, when administered directly into the CNS, is itself
a promising therapeutic to treat NP-C disease (14, 42) and is
currently being evaluated in a clinical trial. Indeed, Alam et al.
(61) recently demonstrated a striking synergy (	2-fold life
extension, relative to 2-hydroxypropyl--cyclodextrin mono-
therapy) when treating Npc1nmf164 mice (in a BALB/c back-
ground) by combining high concentrations of vorinostat with
therapeutic doses of 2-hydroxypropyl--cyclodextrin in a PEG/
DMSO vehicle. Although the confounding effect of using
already therapeutic doses of 2-hydroxypropyl--cyclodextrin
and possibly PEG/DMSO remains to be determined, it is appar-
ent that the pharmacokinetics of vorinostat can be improved.
In summary,NP-Cdisease is a fatal pediatric neurodegenera-
tive disease due to lysosomal accumulation of cholesterol and
FIGURE 10. Transcriptional response of Npc1nmf164 and Npc1/ hepato-
cytes following treatment with vorinostat. Hepatocytes were isolated
from livers of Npc1nmf164 and Npc1/ mice; incubated for 24 h in DMEM 
10% FBS with 10 M vorinostat or DMSO; and assessed for Npc1, Apob, Chop,
Hmgcr, andAbcg1geneexpressionbyqRT-PCR relative to cyclophilin (CYCLO)
and appropriate WT controls using primers described under “Experimental
Procedures.” All groups are n 3with data shown asmean S.D. (error bars)
*, p 0.05, Student’s t test.
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sphingolipids. Currently, there is no effective FDA-approved
therapy to treat NP-C disease. Here we have translated prior
results in a yeastmodel ofNP-Cdisease andNP-Cpatient fibro-
blasts (11) to the Npc1nmf164 mouse model of NP-C disease,
whereinwe report that amarked improvement in liver function
was accompanied by normalized expression of key hepatic
homeostatic genes in vorinostat-treated mice.With these data,
we provide proof of principle that HDAC inhibition has the
potential to be therapeutic in vivo in an animal model of
NP-C disease. Indeed, the potential of vorinostat to amelio-
rate peripheral NPC disease in adults is currently the object
of a Phase 1/2 clinical trial (ClinicalTrials.gov number
NCT02124083).
Our results indicate that vorinostat treatment limits the
aberrant up-regulation of cholesterol biosynthesis and uptake
that arises from lysosomal sequestration of cholesterol in NP-C
disease. Consequently, this markedly improves the visceral
pathophysiology of this disease. With improved blood-brain
barrier penetration, we propose that vorinostat and other
HDAC inhibitors may prove useful for treatment of the neuro-
logical aspects of NP-C disease.
Experimental Procedures
Animals—Animal husbandry and experiments were ap-
proved by theColumbiaUniversity andVictoriaUniversity ani-
mal ethics committees. Animals were exposed to alternating
12-h periods of dark and light and were fed a standard diet, ad
libitum, until dissection. Npc1nmf164 mutant and WT litter-
mates (C57BL/6 background) were generated by crossing
heterozygous Npc1nmf164 males and females. Npc1 genotyping
was conducted by restriction digests of PCR amplicons as
described (17).Mice were i.p. administered with vorinostat (LC
Laboratories) in 10% DMSO and 45% PEG 400, as described
previously (20), from P21 to P60 (for all in vivo experiments
except the body weight/life span experiments, which were con-
tinued to P90). Disease progression was monitored in terms of
weekly weight gain from P21 to P90. For all experiments except
the pharmacokinetic assay, Npc1nmf164 mutant mice and WT
mice were anesthetized 6 h after the last injection with an i.p.
administered injection of ketamine (100 mg/kg) and xylazine
(10 mg/kg), serum was collected, and animals were transcardi-
ally perfused with 0.9% saline solution. Following perfusion,
half of the cerebrum and liver were removed and immediately
frozen at80 °C for genetic and biochemical analysis with the
other half fixed in 4% paraformaldehyde for histological
analysis.
PrimaryHepatocytes andCell Culture—Primary hepatocytes
were isolated from age- and background-matched control,
Npc1nmf164 (C57BL/6 background), and Npc1/ (BALB/c
background, generously provided by X. Huang and S. Walkley)
mice (62). Filtered, washed cells were plated into collagen-
coated 6-well plates at a density of 500,000 viable cells/well in
DMEM  10% FBS. Fibroblasts derived from Npc1nmf164
mutant mice and wild-type littermates or NPC1-deficient
human osteosarcoma U2OS cells expressing the NPC1I1061T
protein were generated andmaintained as described previously
(63).
ApoB Metabolism—For steady-state apoB labeling and
immunoprecipitation, primary hepatocytes were incubated in
methionine-free DMEM for 1 h and then labeled with [35S]me-
thionine in methionine-free DMEM for 2 h (64). Cells were
collected in 200l of lysis buffer (62.5mM sucrose, 0.5% sodium
deoxycholate, 0.5% Triton X-100, 50 mM Tris-HCl, pH 7.4, 150
mMNaCl, 1 mM benzamidine, 5 mM EDTA, 100 units/ml apro-
tinin, 50 g/ml leupeptin, 50 g/ml pepstatin A, and 10 mM
HEPES, pH 8.0) and boiled with sample buffer for 5 min. Tri-
chloroacetic acid total precipitable 35S counts of the cell lysate
were determined and equal radiolabeled intracellular and
medium protein was processed by immunoprecipitation (anti-
lipoprotein B; Calbiochem) and separated on 4% SDS-poly-
acrylamide gels. The gels were dried under vacuum at 65 °C for
2 h and exposed to X-ray films to visualize apoB100 and
apoB48.
RNA-Seq Analysis—Total RNA was extracted from livers of
Npc1nmf164 vehicle control and vorinostat-treated mice (7 ani-
mals/group) using the PureLink RNA minikit (Life Technolo-
gies) and processed for RNA-Seq analyses at the Australian
Genome Research Facility. RNA-Seq libraries were prepared
using the TruSeq RNA version 2 kit (Illumina) and quantified
using Bioanalyzer (Agilent). The prepared libraries were
sequenced using an Illumina HiSeq 2000 (100-bp single end
reads). The reads were mapped to the Mus musculus genome
(Build version mm10) using TopHat (version 2.0.13). Tran-
scripts were assembled utilizing reference-based annotation
with Cufflinks (version 2.2.1). Gene expression was normalized
and quantified using trimmed mean of M values. Differential
gene expression analysis of vorinostat-treated mice relative to
vehicle-treated mice was calculated using log2 ratio (-fold
change) and statistically evaluated using edgeR. The data set
has been deposited in the NCBI GEO database. Gene ontology
processes of differentially expressed genes were classified using
PANTHER (protein analysis through evolutionary relation-
ships) andMGD (Mouse GenomeDatabase) (65, 66). The web-
based Gene Set Analysis Toolkit (34) was used to conduct
enrichment analyses of functions and pathways. Phenolyzer
(35) was used to identify core components of the vorinostat
interactome.
qRT-PCR—Gene expression was measured using qRT-PCR.
For validation of RNA-Seq results, 80 ng of total RNAwas con-
verted to mRNA using the Power SYBR Green RNA-to-CT kit
(Applied Biosystems) and quantified using SYBR Green chem-
istry and a CFX Connect real-time PCR detection system (Bio-
Rad). For characterization of primary hepatocytes, RNA was
isolated from cells with TRIzol (Invitrogen) and was used as a
template in qRT-PCR using an Applied Biosystems 7900HT
sequence detection system. The mRNA levels were calculated
by the 2CT method (67) using the following 5
 to 3
 primer
sequences: Abcg1 (forward, GCTGTGCGTTTTGTGCTGTT;
reverse, TGCAGCTCCAATCAGTAGTCCTAA) (14); ApoB
(forward, CTGGGCTCCAGCATTCTA; reverse, TCAC-
CAGTCATTTCTGCCTTTG) (68); Chop (forward, CACCA-
CACCTGAAAGCAGAAC; reverse, GGTGAAAGGCA-
GGGACTCA) (69); Cyclo (forward, TGGAGAGCACCAAG-
ACAGACA; reverse, TGCCGGAGTCGACAATGAT) (70);
Cyp51 (forward, CCTGGATGGAGGTTTTACCC; reverse,
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TCTCTCGATGGGCTCTATCC); Gapdh (forward, TGG-
CGCCTGTGTCTGTGT; reverse, TCGGGTCTGATTTCT-
GTTTCTTC) (29);Hmgcr (forward, CTTGTGGAATGCCTT-
GTGATTG; reverse, AGCCGAAGCAGCACATGAT) (14);
Hmgcs (forward, GCCGTGAACTGGGTCGAA; reverse,
GCATATATAGCAATGTCTCCTGCAA) (14); Idi1 (forward,
AAAGCCGAGTTGGGAATACCC; reverse, ACCATCA-
GATTGGGCCTTGTA); Ldlr (forward, GAGGAACTGGCG-
GCTGAA; reverse, GTGCTGGATGGGGAGGTCT) (14); Lss
(forward, GCGGCTGTGCGATGCT; reverse, AGGTAGC-
GAACCCGCCA); Mvd (forward, CCGGTCAACATCG-
CAGTTATC; reverse, TTGTGGTCGTTTTTAGCTGGT);
Mvk (forward, GGTGTGGTCGGAACTTCCC; reverse, CCT-
TGAGCGGGTTGGAGAC); Npc1 (forward, AACCGTGA-
CACTGCAGGACAT; reverse, CTCATAATGGTGCA-
GTTCTTGTTGT) (46); and Npc2 (forward, TGGCGCCT-
GTGTCTGTGT; reverse, TCGGGTCTGATTTCTGT-
TTCTTC) (46). Primers without references were designed
using Primer-BLAST (71).
Immunoblotting and Deglycosylation—Frozen liver was
homogenized in radioimmune precipitation assay buffer with
the addition of protease inhibitors (RocheApplied Science) and
centrifuged at 16,000 g. Protein concentration wasmeasured
using the BCA protein assay (Bio-Rad). For deglycosylation,
protein extracts were combined with glycoprotein denatur-
ation buffer (5% SDS, 0.4 M DTT), denatured at 65 °C for 10
min, treated with either GlycoBuffer 3 (New England Biolabs)
and 1000 units of Endo H (New England Biolabs) or Glyco-
Buffer 2 (NewEngland Biolabs) with 1%Nonidet P-40 and 1000
units of PNGase F (New England Biolabs), and incubated at
37 °C for 7 h. Protein was denatured at 4 °C for 30 min, loaded
onto a 7.5% BisTris gel, subjected to electrophoresis, trans-
ferred onto 0.2 M PVDF membranes using a semidry system
(Bio-Rad), and incubated with NPC1 antibody (Abcam
ab134113 or Abcam ab36983) or actin antibody (Sigma).Mem-
branes were probed with goat anti-mouse or goat anti-rabbit
secondary antibodies (GEHealthcare), visualized using ECL-
plus (GE Healthcare) with a fluorescent image analyzer
(Fuji FLA-5100), and quantified using densitometry software
(ImageJ).
NPC1 Protein Refolding—Cells were incubated in the pres-
ence and absence of glycerol, 3-methyladenine, MG132, or lac-
tacystin for 20 h at 37 °C, lysed in 100 mM sodium phosphate,
pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% IGEPAL CA-630 for 15
min at 4 °C, and centrifuged for 5 min at 14,000 rpm at 4 °C.
Total cell lysates were denatured at 70 °C for 10 min, subjected
to SDS-PAGE through a 3–8% Tris acetate precast gel (Invit-
rogen), transferred to nitrocellulose membrane (Protran), and
probed using primary antibodies against NPC1 (Abcam
ab134113) or Hsp70 (Millipore) and a secondary HRP-conju-
gated rabbit IgG (GE Healthcare). Proteins were visualized by
chemiluminescence using SuperSignal West Dura substrate
(Thermo Scientific) on a FluorChemQ imager (ProteinSimple)
using AlphaView software (Alpha Innotech).
Pharmacokinetics—Vorinostat (150 mg/kg) was adminis-
tered as described above with one injection inNpc1nmf164mice.
Plasma and brain were collected at 30, 60, 120, and 240 min
after the injection. Vorinostat levels were measured using
LC-MS/MS as described previously (43).
Serum Analysis—Serum measurements of ALT total choles-
terol, HDL cholesterol, LDL cholesterol, and triglyceride were
assessed at a commercial laboratory (New Zealand Veterinary
Pathology) as part of a general metabolic profile.
Histology—Fixed liver tissue was paraffin-embedded, and
5-msectionswere stainedwithH&Eby theColumbiaUniver-
sity Medical Center Molecular Pathology Core Facility. The
prevalence of lipid-laden cells was expressed as a fraction of
total cells per field and quantified using SlidePath tissue image
analysis (Leica Biosystems, version 2.0) software at 20
magnification.
Lipids—Homogenized frozen tissue (half liver lobe) was used
to prepare lipids by a modified Bligh and Dyer extraction pro-
cedure (72). Free cholesterol, sphingomyelin, sphingosine,
glucosylceramide, and lactosylceramide were measured using
LC/MS as described previously (73, 74) modified for use with a
Shimadzu 8040 LC/MS system, an APCI source with MRM
detection, and a Waters Acquity BEH C18 1.7-m, 2.1 
150-mmcolumn. Standards (Avanti Polar Lipids) were used for
quantification, and all measurements were normalized to liver
weight. Subcellular accumulation of free cholesterol in liver
sectionswas visualized using fluorescence of filipin as described
previously (42) and quantified using densitometry software
(ImageJ).
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